Effectiveness of Erythropoietin in Elderly Coronary Bypass Patients / 日本心臓血管外科学会雑誌

ABSTRACT

The effectiveness of recombinant human erythropoietin (rHuEPO) was evaluated in elderly patients who underwent coronary artery bypass grafting. A total of 133 patients were divided into three groups those who were 70 years of age or older and received rHuEPO (group I; <i>n</i>=32), those who were also 70 years of age or older but did not receive rHuEPO (group II; <i>n</i>=35), and those who were 60 years or younger and received rHuEPO (group III; <i>n</i>=66). In 87.5% of group I, 42.9% of group II, and 98.5% of group III, homologous blood transfusion could be avoided. The percentage of patients without homologous blood transfusion was significantly higher in group I than in group II (<i>p</i><0.001). The rate of homologous blood transfusion was significantly higher in group I than in group III (<i>p</i><0.05), but rHuEPO had equal effects in terms of increase in hemoglobin level in the two groups. Furthermore, in patients without anemia, the rate of homologous blood transfusion was almost the same in the two groups. In conclusion, the administration of rHuEPO enables even elderly patients to undergo coronary artery bypass grafting without homologous blood transfusion.